Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.8K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

184
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
184
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

928
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
928
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

85
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
85
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

113
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
113

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Outcomes of Complete Revascularization in Acute Myocardial Infarction Patients With High Bleeding Risk and Multivessel Disease.

Journal of the American Heart Association·2026
Same author

The Persistent Challenge of Cardiogenic Shock Complicating Acute Myocardial Infarction: Insights From a Korean Nationwide Registry.

Korean circulation journal·2026
Same author

Hemodynamic Profile, Clinical Outcomes, and Potential Transplant Candidacy in Patients With Portopulmonary Hypertension.

Korean circulation journal·2026
Same author

Coronary Computed Tomographic Angiography Versus Functional Testing in Patients With Newly Diagnosed Type 2 Diabetes and Suspected Coronary Artery Disease: Real-world Evidence from the Nationwide Cohort.

Korean circulation journal·2026
Same author

Sex Differences in Prognostic Implications of CYP2C19 Genotype After Drug-Eluting Stent Implantation.

Journal of the American Heart Association·2026
Same author

Effects of increasing intranuclear calcium levels via MCU inhibition on mouse and human PSC-derived cardiomyocyte differentiation and maturation.

Stem cells translational medicine·2026

Related Experiment Video

Updated: Dec 13, 2025

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.2K

Ethnic Differences in Oral Antithrombotic Therapy.

Haechan Cho1, Jeehoon Kang1, Hyo Soo Kim1

  • 1Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital, Seoul, Korea.

Korean Circulation Journal
|July 30, 2020
PubMed
Summary

East Asians may require different oral antithrombotic therapy due to unique responses. This review explores ethnicity-related differences to develop targeted cardiovascular disease treatment strategies.

Keywords:
AnticoagulationAntiplatelet therapyEthnic differenceOral anthrombotic therapy

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K
In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.0K

Related Experiment Videos

Last Updated: Dec 13, 2025

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.2K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K
In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.0K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Clinical Pharmacy

Background:

  • Oral antithrombotic therapy, including antiplatelet and anticoagulation, is crucial for cardiovascular disease (CV) management.
  • Existing research suggests potential ethnic variations in therapeutic requirements and responses to antithrombotic agents.
  • East Asian populations may exhibit distinct patterns, with lower ischemic event rates but higher bleeding risks compared to Western populations.

Purpose of the Study:

  • To review and describe ethnicity-related differences in oral antithrombotic therapy for cardiovascular disease.
  • To highlight the specific considerations for East Asian patients undergoing antithrombotic treatment.
  • To advocate for the development of tailored antithrombotic strategies for East Asian populations.

Main Methods:

  • Literature review and synthesis of existing studies on antithrombotic therapy and ethnicity.
  • Analysis of reported outcomes (ischemic and bleeding events) across different ethnic groups.
  • Discussion of clinical implications and future research directions.

Main Results:

  • Evidence suggests significant ethnic variations in the efficacy and safety of antithrombotic therapies.
  • East Asians appear to have a different risk-benefit profile, with reduced ischemic outcomes and increased bleeding complications.
  • Current treatment guidelines may not adequately address these ethnicity-specific differences.

Conclusions:

  • Ethnicity is a critical factor influencing antithrombotic therapy outcomes in cardiovascular disease.
  • A personalized approach to antithrombotic treatment is necessary, particularly for East Asian patients.
  • Further research is essential to refine antithrombotic strategies for diverse ethnic groups to optimize patient care.